Therapeutic antibody site modification information management system and method, terminal and medium
By designing a therapeutic antibody site transformation information management system, integrating information from multiple sources, standardizing the processing and evaluating antibody site transformation, the problem of insufficient stability and bioavailability of antibody drugs is solved, and the development and transformation efficiency is improved.
Patent Information
- Application Number
- CN202310567237.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively integrate and standardize the processing of therapeutic antibody site modification information from multiple sources, resulting in insufficient stability and bioavailability of antibody drugs and great pressure for development and transformation.
A therapeutic antibody site transformation information management system was designed, including resource library management, site transformation information management and antibody sequence evaluation system. Through resource library management, a multi-resource knowledge base is built, and antibody site transformation information is standardized, and an evaluation is evaluated. and recommend modification plans to improve the developability of antibody sequences.
The systematic collection, standardized organization and storage of antibody site transformation information has been realized, the stability and bioavailability of antibody drugs have been improved, the development and transformation process has been simplified, and the research and development and production process has been accelerated.
Smart Images

Figure CN119007806A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of bioinformatics, and in particular to a therapeutic antibody site modification information management system, method, terminal and medium. Background Art
[0002] Since the 1990s, with the continuous development of polymerase chain reaction technology, antibody library technology, transgenic technology, etc., monoclonal antibodies have been more and more widely used in the diagnosis and treatment of tumors, autoimmune diseases, infectious diseases and other fields. In addition to monoclonal antibodies, various forms of therapeutic antibodies such as bispecific antibodies, nanobodies, antibody conjugates, etc. are constantly emerging and gradually approved for marketing.
[0003] As a kind of artificially synthesized protein, monoclonal antibody is easily affected by the physical and chemical aspects of the complex environment in vivo and in vitro during production, storage and in vivo use, and various forms of physical and chemical property changes occur, which in turn lead to increased immunogenicity, shortened half-life, and even failure. Therefore, how to improve the stability of antibody drugs, reduce immunogenicity, prolong half-life, and improve their in vivo bioavailability are key issues that need to be solved in the current application of antibody drugs. Not only monoclonal antibodies, but other types of therapeutic antibodies also need to be engineered to improve stability and reduce side effects.
[0004] There are now many ways to engineer antibodies to improve their performance, such as glycosylation, controlling post-translational modifications to regulate antibody charge heterogeneity, and amino acid mutations to improve antibody stability. Although antibody modification can now use many experimental or computational methods, antibody development and modification still face many challenges. Using knowledge bases to assist the development and modification of therapeutic antibodies is a new solution.
[0005] The knowledge base built by integrating relevant knowledge from various sources has been applied and promoted in many fields. In the field of therapeutic antibodies, there are also methods for building knowledge bases related to antibody sequences, knowledge bases that integrate antibody information in patents, and knowledge base construction methods in other fields, which provide references for using knowledge bases to perform site modification of therapeutic antibodies. However, it is difficult for the existing methods and schemes to extract and store knowledge from various sources in a standardized manner, and it is difficult to directly use them for site modification of therapeutic antibodies. As people's demand for therapeutic antibodies becomes more and more urgent and the pressure for development and modification is increasing, it is urgent and necessary to develop a knowledge base that integrates information on therapeutic antibody site modification from multiple sources and uses the knowledge base to evaluate antibody sequences and make modification recommendations. Summary of the invention
[0006] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a therapeutic antibody site modification information management system, method, terminal and medium to solve the above-mentioned prior art problems.
[0007] To achieve the above-mentioned purpose and other related purposes, the present invention provides a therapeutic antibody site modification information management system, the system comprising: a resource library management system, used to perform resource library management on each resource corresponding to the collected antibody site modification information source, so as to construct a source resource library containing multiple resources; wherein each resource in the source resource library corresponds to a resource number and a resource status; a site modification information management system, connected to the resource library management system, used to perform site modification information storage and judgment on the antibody site modification information in the resources extracted from the source resource library, and perform site modification information normalization on the antibody site modification information that meets the storage conditions, so as to construct a knowledge base containing multiple antibody site modification information with normalized site information; wherein each antibody site modification information in the knowledge base corresponds to a site coordinate number, a site modification factor, a change in antibody performance before and after the site modification, and a site modification information source score; an antibody sequence evaluation system, connected to the site modification information A management system is used to number the site coordinates of each site of one or more antibody sequences to be modified that meet the therapeutic antibody type specified in the knowledge base, and evaluate the dominant sites and disadvantageous sites of each antibody sequence based on the knowledge base to obtain the evaluation results of each antibody sequence, so as to rank the antibody sequences for modification based on the evaluation results of each antibody sequence; wherein the evaluation results of each antibody sequence include: the number of dominant sites, the number of disadvantageous sites, and the site modification factors corresponding to the dominant sites and the disadvantageous sites respectively; a modification scheme recommendation system is connected to the site modification information management system, and is used to number the site coordinates of each site of the antibody sequence to be recommended for the modification scheme of the therapeutic antibody type specified in the knowledge base, and evaluate the risk sites of the antibody sequence based on the knowledge base, and obtain the modification recommendation scheme of the antibody sequence; wherein the modification recommendation scheme includes: the site information before and after the modification, and the site modification factors corresponding to each site information and the site modification information source score.
[0008] In one embodiment of the present invention, the resource library management system includes: a resource number management module, which is used to number each resource of the newly collected corresponding antibody site modification information source according to the numbering rule; a resource entry management module, connected to the resource number management module, used to query whether there is a corresponding resource in the current source resource library based on the number of each resource, and incorporate the resources that do not exist in the source resource library into the source resource library; a resource status management module, connected to the resource entry management module, used to assign a resource status of a corresponding resource unprocessed state to the resource newly incorporated into the source resource library; a resource processing management module, connected to the resource status management module, used to extract the resources required by the site modification information management system from the source resource library and send them to the site modification information management system for processing and return the corresponding resources to the source resource library after processing, and send the processing status of the resources to the resource status management module in real time to update the resource status of the corresponding resources in real time; wherein the types of resource status include: resource unprocessed state, resource processing state, resource adopted state, resource not adopted state and resource shelved state; a resource query management module, used to query and statistically analyze the resources in the source resource library using resource numbers and / or resource states.
[0009] In one embodiment of the present invention, the site modification information management system includes: a modification information storage and judgment module, which is used to perform site modification information storage and judgment on the antibody site modification information in the resources extracted from the source resource library; a site information normalization module, connected to the modification information storage and judgment module, which is used to normalize the site information of the antibody site modification information that meets the storage conditions; a knowledge base update module, connected to the site information normalization module, which is used to determine whether the antibody site modification information after site information normalization exists in the knowledge base; if it is determined to exist in the knowledge base, it is determined whether to update the knowledge base based on the site modification information source score corresponding to the antibody site modification information; if it is determined that it does not exist in the knowledge base, the antibody site modification information after site information normalization is placed in the knowledge base.
[0010] In one embodiment of the present invention, the modification information storage judgment module includes: a therapeutic antibody type management module, which is used to determine whether the therapeutic antibody type of the antibody site modification information in the resources extracted from the source resource library is the therapeutic antibody type specified by the knowledge base, and if so, it meets the first storage condition; a site modification factor management module, which is connected to the therapeutic antibody type management module, and is used to determine whether the site modification factor of the antibody site modification information that meets the first storage condition is the site modification factor specified by the knowledge base, and if so, it meets the second storage condition; a site modification type management module, which is connected to the site modification factor management module, and is used to determine whether the site modification type of the antibody site modification information that meets the second storage condition is the site modification type specified by the knowledge base, and if so, it meets the storage condition.
[0011] In one embodiment of the present invention, the site information normalization module includes: a site coordinate management module, which is used to use a preset numbering system to number the site coordinates of the sites of the antibody site modification information that meet the storage conditions; a modification site information scoring management module, which is used to score the credibility of the antibody site modification information based on the resources of the source of the antibody site modification information to obtain the site modification information source score of the corresponding antibody site modification information; a management module for antibody performance changes before and after site modification, which is used to determine the antibody performance changes before and after the site modification of the antibody site modification information; wherein the antibody performance changes before and after the site modification include: changes without obvious changes, changes with better performance, and changes with worse performance.
[0012] In one embodiment of the present invention, the method for determining whether to update the knowledge base based on the site modification information source score corresponding to the antibody site modification information includes: comparing the site modification information source score corresponding to the antibody site modification information with the site modification information source score of the same antibody site modification information existing in the knowledge base; if the site modification information source score corresponding to the antibody site modification information is smaller than the site modification information source score of the antibody site modification information in the knowledge base, the knowledge base is not updated; if the site modification information source score corresponding to the antibody site modification information is larger than the site modification information source score of the antibody site modification information in the knowledge base, the antibody site modification information in the knowledge base is updated; if the site modification information source score corresponding to the antibody site modification information is the same as the site modification information source score of the antibody site modification information in the knowledge base, manually selecting whether to update the antibody site modification information in the knowledge base.
[0013] In one embodiment of the present invention, the antibody sequence evaluation system includes: a type recognition module, which is used to determine whether the therapeutic antibody type of each antibody sequence to be modified is the therapeutic antibody type specified in the knowledge base; a site coordinate numbering module, connected to the type recognition module, which is used to use the preset numbering system adopted by the site coordinate management module to perform site coordinate numbering on each site of each antibody sequence to be modified that meets the therapeutic antibody type for constructing the knowledge base; a dominant site evaluation module, which is connected to the site coordinate numbering module, which is used to check whether there is modified site information obtained in the knowledge base according to the change of better performance in each antibody sequence based on the site coordinate numbering of each antibody sequence; if so, determine the site modification factor corresponding to the site information, and use the site of the site information as the dominant site; the inferior site A point evaluation module is connected to the site coordinate numbering module, and is used to check whether there is modified site information obtained in the knowledge base according to the change in performance degradation in each antibody sequence based on the site coordinate number of each antibody sequence; if so, the site modification factor corresponding to the site information is determined, and the site of the site information is used as a disadvantageous site; an evaluation result generation module is connected to the dominant site evaluation module and the inferior site evaluation module, and is used to count the number of dominant sites, the number of inferior sites, and the site modification factors corresponding to each site of each sequence based on the dominant sites and the site modification factors corresponding to the dominant sites and the site modification factors corresponding to the inferior sites of each antibody sequence, and obtain the evaluation result of each antibody sequence, so as to carry out the modification sorting of each antibody sequence based on the number of inferior sites of each antibody sequence.
[0014] In one embodiment of the present invention, the modification scheme recommendation system includes: a type identification module, which is used to determine whether the therapeutic antibody type of the antibody sequence of the modification scheme to be recommended is the therapeutic antibody type specified in the knowledge base; a site coordinate numbering module, which is connected to the type identification module and is used to use the preset numbering system adopted by the site coordinate management module to perform site coordinate numbering on each site of the antibody sequence of the modification scheme to be recommended that meets the therapeutic antibody type for constructing the knowledge base; a risk site assessment module, which is connected to the site coordinate numbering module and is used to check whether there is modified site information obtained in the knowledge base according to the change in performance degradation in each antibody sequence based on the site coordinate numbering of each antibody sequence; if so, determine the corresponding site information. The method comprises the following steps: determining the site transformation factor of the point information based on the site coordinate number of each antibody sequence, and taking the site as a risk site; checking whether there is site information before transformation obtained in the knowledge base according to a change with better performance in each antibody sequence based on the site coordinate number of each antibody sequence; if so, determining the site transformation factor of the corresponding site information, and taking the site as a risk site; a transformation plan generating module, connected to the risk site evaluation module, for using the site coordinate number of each risk site to check whether there is site information before transformation obtained in the knowledge base according to a change with better performance; if so, obtaining the corresponding site information before and after transformation, as well as the site transformation factor and the site transformation information source score corresponding to each site information, so as to generate a corresponding transformation recommendation plan.
[0015] To achieve the above-mentioned purpose and other related purposes, the present invention provides a method for managing therapeutic antibody site modification information, the method comprising: constructing a knowledge base of therapeutic antibody site modification information; based on the constructed knowledge base, performing antibody evaluation on one or more antibody sequences to be modified and / or performing modification recommendations on antibody sequences for which modification schemes are to be recommended; wherein the method for constructing the knowledge base of therapeutic antibody site modification information comprises: performing resource library management on each resource corresponding to the source of the collected antibody site modification information to construct a source resource library containing multiple resources; wherein each resource in the source resource library corresponds to a resource number and a resource status; performing site modification information storage and judgment on the antibody site modification information extracted from the source resource library, and performing site information normalization on the antibody site modification information that meets the storage conditions to construct a knowledge base containing multiple antibody site modification information after site information normalization; wherein each antibody site modification information in the knowledge base corresponds to a site coordinate number, a site modification factor, a change in antibody performance before and after site modification, and a site status. site modification information source score; a method for evaluating one or more antibody sequences to be modified includes: numbering the site coordinates of each site of one or more antibody sequences to be modified that meet the therapeutic antibody type specified in the knowledge base, and evaluating the dominant sites and the inferior sites of each antibody sequence based on the knowledge base to obtain the evaluation results of each antibody sequence, so as to rank the modification of each antibody sequence based on the evaluation results of each antibody sequence; wherein the evaluation results of each antibody sequence include: the number of dominant sites, the number of inferior sites, and the site modification factors corresponding to the dominant sites and the inferior sites respectively; a method for recommending modification of an antibody sequence for which a modification scheme is to be recommended includes: numbering the site coordinates of each site of an antibody sequence for which a modification scheme is to be recommended that meets the therapeutic antibody type specified in the knowledge base, and evaluating the risk sites of the antibody sequence based on the knowledge base, and obtaining a modification recommendation scheme for the antibody sequence for recommendation; wherein the modification recommendation scheme includes: site information before and after modification, and site modification factors corresponding to each site information and a site modification information source score.
[0016] To achieve the above-mentioned purpose and other related purposes, the present invention provides a therapeutic antibody site modification information management terminal, comprising: one or more memories and one or more processors; the one or more memories are used to store computer programs; the one or more processors are connected to the memories and are used to run the computer program to execute the therapeutic antibody site modification information management method.
[0017] To achieve the above objectives and other related objectives, the present invention provides a computer-readable storage medium storing a computer program, which executes the therapeutic antibody site modification information management method when executed by one or more processors.
[0018] As described above, the present invention is a therapeutic antibody site modification information management system, method, terminal and medium, which has the following beneficial effects: the present invention constructs a source resource library by managing the resources of the corresponding antibody site modification information source collected, collects and judges the antibody site modification information in the resources extracted from the source resource library, and standardizes the site information of the antibody site modification information that meets the storage conditions to construct a knowledge base; based on the knowledge base, the antibody sequence to be modified is evaluated for advantageous sites and disadvantageous sites to obtain the evaluation results, and the antibody sequence to be recommended for the modification scheme is evaluated for risk sites to obtain the modification recommendation scheme of the antibody sequence. The present invention realizes the systematic collection and update of antibody site modification information, standardized arrangement, storage, and formation of a knowledge base, and can use this knowledge base to realize the evaluation of the development potential of the antibody sequence to be modified, sorting, and recommendation of modification opinions. This will facilitate antibody developers and other personnel to use a large amount of existing knowledge to quickly and economically develop and modify antibody sequences, and accelerate the research and development, production and other processes of antibody drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Shown is a schematic diagram of the structure of a therapeutic antibody site modification information management system in one embodiment of the present invention.
[0020] Figure 2 Shown is a schematic diagram of the structures of a resource library management system and a site modification information management system in one embodiment of the present invention.
[0021] Figure 3 Shown is a schematic diagram of a method for managing a source resource library in an embodiment of the present invention.
[0022] Figure 4 Shown is a schematic diagram of the structure of a site modification information management system in one embodiment of the present invention.
[0023] Figure 5 Shown is a schematic diagram of the site modification information processing flow in one embodiment of the present invention.
[0024] Figure 6 Shown is a schematic diagram of the structure of an antibody sequence evaluation system in one embodiment of the present invention.
[0025] Figure 7 Shown is a schematic diagram of the structure of a transformation solution recommendation system in one embodiment of the present invention.
[0026] Figure 8 Shown is a schematic diagram of the process of a method for managing therapeutic antibody site modification information in one embodiment of the present invention.
[0027] Fig. 9Shown is a schematic flow chart of a method for constructing a knowledge base of therapeutic antibody site modification information in one embodiment of the present invention.
[0028] Fig.10 It is a schematic diagram of a process for performing antibody evaluation in one embodiment of the present invention.
[0029] Fig.11 Shown is a flowchart of a method for performing a modification recommendation in one embodiment of the present invention.
[0030] Fig.12 Shown is a schematic diagram of the structure of a therapeutic antibody site modification information management terminal in one embodiment of the present invention. DETAILED DESCRIPTION
[0031] The following describes the embodiments of the present invention by specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that the following embodiments and features in the embodiments can be combined with each other without conflict.
[0032] It should be noted that in the following description, reference is made to the accompanying drawings, which describe several embodiments of the present invention. It should be understood that other embodiments may also be used, and that composition, structure, electrical and operational changes may be made without departing from the spirit and scope of the present invention. The following detailed description should not be considered restrictive, and the scope of the embodiments of the present invention is limited only by the claims of the published patents. The terms used herein are only for describing specific embodiments and are not intended to limit the present invention. Spatially related terms, such as "upper", "lower", "left", "right", "below", "below", "lower", "above", "upper", etc., may be used in the text to facilitate the description of the relationship between an element or feature shown in the figure and another element or feature.
[0033] Throughout the specification, when a part is said to be "connected" to another part, this includes not only the case of "direct connection" but also the case of "indirect connection" by placing other elements therebetween. In addition, when a part is said to "include" a certain constituent element, unless otherwise stated, it does not exclude other constituent elements, but means that other constituent elements may be included.
[0034] The terms first, second and third mentioned herein are used to describe various parts, components, regions, layers and / or segments, but are not limited thereto. These terms are only used to distinguish a certain part, component, region, layer or segment from other parts, components, regions, layers or segments. Therefore, the first part, component, region, layer or segment described below may refer to the second part, component, region, layer or segment within the scope of the present invention.
[0035] Furthermore, as used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless there is an indication to the contrary in the context. It should be further understood that the terms "comprise", "include" indicate the presence of the described features, operations, elements, components, items, kinds, and / or groups, but do not exclude the presence, occurrence or addition of one or more other features, operations, elements, components, items, kinds, and / or groups. The terms "or" and "and / or" used herein are interpreted as inclusive, or mean any one or any combination. Therefore, "A, B or C" or "A, B and / or C" means "any of the following: A; B; C; A and B; A and C; B and C; A, B and C". Exceptions to this definition will only occur when the combination of elements, functions or operations is inherently mutually exclusive in some way.
[0036] Explanation of relevant terms involved in the present invention:
[0037] Antibody: An immunoglobulin secreted by effector B cells that is used to identify and eliminate exogenous substances such as bacteria and viruses.
[0038] Therapeutic antibodies: Antibodies have a wide range of applications, such as in vitro antigen detection and labeling, among which therapeutic antibodies can be used as drugs to directly treat diseases.
[0039] Antibody modification: Use engineering methods to modify the structure of antibody molecules to improve antibody stability, optimize affinity, etc., and enhance the potential for development into antibody drugs.
[0040] Knowledge base: A special database that contains a set of rules and related data. Its orderly storage and management of information and rules helps to quickly and efficiently perform correlation analysis around specific needs and provide support for decision-making.
[0041] A therapeutic antibody site modification information management system of the present invention constructs a source resource library by managing the collected resources of the corresponding antibody site modification information sources, collects and judges the antibody site modification information in the resources extracted from the source resource library, and standardizes the site information to construct a knowledge base for the antibody site modification information that meets the storage conditions; based on the knowledge base, the antibody sequence to be modified is evaluated for advantageous sites and disadvantageous sites to obtain the evaluation results, and the antibody sequence to be recommended for the modification scheme is evaluated for risk sites to obtain the modification recommendation scheme of the antibody sequence. The present invention realizes the systematic collection and update of antibody site modification information, standardized arrangement, storage, and formation of a knowledge base, and can use this knowledge base to realize the evaluation of the developability potential of the antibody sequence to be modified, sorting, and recommendation of modification opinions. This will facilitate antibody developers and other personnel to use a large amount of existing knowledge to quickly and economically develop and modify antibody sequences, and accelerate the research and development, production, and other processes of antibody drugs.
[0042] The following is a detailed description of the embodiments of the present invention with reference to the accompanying drawings so that those skilled in the art can easily implement the present invention. The present invention can be embodied in many different forms and is not limited to the embodiments described herein.
[0043] like Figure 1 A schematic diagram showing the structure of a therapeutic antibody site modification information management system in an embodiment of the present invention.
[0044] The structure comprises:
[0045] A resource library management system 1 is used to manage the collected resources corresponding to the antibody site modification information source to construct a source resource library containing multiple resources; wherein each resource in the source resource library corresponds to a resource number and a resource status;
[0046] The site modification information management system 2 is connected to the resource library management system 1, and is used to perform site modification information storage and judgment on the antibody site modification information in the resources extracted from the source resource library, and to perform site modification information normalization on the antibody site modification information that meets the storage conditions, so as to construct a knowledge base containing a plurality of antibody site modification information after site modification information normalization; wherein each antibody site modification information in the knowledge base respectively corresponds to a site coordinate number, a site modification factor, a change in antibody performance before and after site modification, and a site modification information source score;
[0047] The antibody sequence evaluation system 3 is connected to the site modification information management system 2, and is used to number the site coordinates of each site of one or more antibody sequences to be modified that meet the therapeutic antibody type specified in the knowledge base, and evaluate the dominant sites and the inferior sites of each antibody sequence based on the knowledge base to obtain the evaluation results of each antibody sequence, so as to perform modification sorting on each antibody sequence based on the evaluation results of each antibody sequence; wherein the evaluation results of each antibody sequence include: the number of dominant sites, the number of inferior sites, and the site modification factors corresponding to the dominant sites and the inferior sites respectively;
[0048] The modification scheme recommendation system 4 is connected to the site modification information management system 2, and is used to number the site coordinates of each site of the antibody sequence of the therapeutic antibody type to be recommended for the modification scheme that meets the requirements of the knowledge base, and to evaluate the risk sites of the antibody sequence based on the knowledge base, and obtain the modification recommendation scheme of the antibody sequence; wherein the modification recommendation scheme includes: the site information before and after the modification, and the site modification factors corresponding to each site information and the site modification information source score.
[0049] In order to better describe the construction method of the knowledge base of the site modification information of therapeutic antibodies, it is now explained in conjunction with the following specific examples.
[0050] The provided method for constructing a knowledge base of site modification information mainly based on therapeutic antibodies is mainly realized through a resource library management system and a site modification information management system. By standardizing the management of data and site information, a structured and traceable knowledge base of therapeutic antibody site modification information can be generated. This provides a new solution for effectively organizing and storing information scattered in different resources.
[0051] The following describes the method of managing a resource library using a resource library management system in conjunction with a specific embodiment.
[0052] The information on therapeutic antibody site modification comes from a variety of sources, such as literature reports, information accumulated during antibody development, information disclosed when drugs are marketed, etc. These are all resources for site modification knowledge sources. We use resource libraries to manage these resource information.
[0053] In one embodiment, if Figure 2 As shown, the resource library management system 1 includes:
[0054] The resource numbering management module 11 is used to number each newly collected resource corresponding to the antibody site modification information source according to the numbering rules; specifically, when new resources are collected, the obtained resources are numbered according to the established numbering rules (such as using PubMed numbers for literature resources, etc.).
[0055] The resource entry management module 12 is connected to the resource number management module 11 and is used to query whether there is a corresponding resource in the current source resource library based on the number of each resource, and incorporate the resources that do not exist in the source resource library into the source resource library; specifically, query whether the resource already exists in the resource library based on the number, exclude the resources that already exist in the library, and prevent duplicate collection of resources;
[0056] The resource status management module 13 is connected to the resource storage management module 12, and is used to assign a resource status corresponding to the unprocessed resource status to the resources newly included in the source resource library; specifically, the de-redundant resources are finally included in the resource library and assigned corresponding status according to the resource status management plan; generally speaking, a resource status corresponding to the unprocessed resource status is assigned to the resources newly included in the source resource library; wherein the types of resource status include: unprocessed resource status, resource processing status, adopted resource status, non-adopted resource status and shelved resource status; wherein the unprocessed resource status indicates that the site transformation information in this resource has not yet been sorted out; the resource processing status indicates that the resource has been extracted from the source resource library, and the site transformation information is being sorted out. Set the "resource processing status" to avoid a resource being processed at the same time, resulting in redundancy of site information; the resource adoption status indicates that part or all of the site modification information in the resource is included in the knowledge base; the resource non-adopting status indicates that all site modification information in the resource is not included in the knowledge base, and this part of the resource is still retained in the resource library to prevent the same resource from being collected again; the resource shelving status indicates that the site modification information in the resource does not meet the current knowledge base inclusion standards for the time being, but is still valuable and can be left for subsequent knowledge base iterations to continue processing. At the same time, the resource shelving status can coexist with the resource adoption status in the same resource. Setting the resource shelving status can retain resources to the maximum extent and quickly provide relevant resources for the iteration of the knowledge base.
[0057] The resource processing management module 14 is connected to the resource status management module 13, and is used to extract the resources required by the site modification information management system from the source resource library and send them to the site modification information management system for processing, and return the corresponding resources to the source resource library after processing, and send the processing status of the resources to the resource status management module in real time to update the resource status of the corresponding resources in real time; specifically, when it is necessary to extract relevant site modification knowledge from the resources, first extract the resources of the specified status from the resource library, such as the resources in the unprocessed state, and at the same time, the resource status of the extracted resources is set to the resource processing state by the resource status management module 13 according to the resource status management plan; then process the resources; finally, return the resources to the resource library, and at the same time, the resource status management module 13 manages the status of the returned resources according to the actual situation of resource processing. The collection, storage and processing of resources are managed independently, which makes the management of resources more flexible, such as Figure 3 shown.
[0058] The resource query management module is used to query and perform statistical analysis on the resources in the source resource library using the resource number and / or resource status, so as to grasp the status of the entire resource library at any time.
[0059] The following describes the manner in which the site modification information management system manages site modification information in conjunction with specific embodiments.
[0060] Different types of resources have different records of site modification information, and even the same type of resources have different records of modification information. The site modification information acquisition and organization method can be used to obtain and save site modification information in a standardized manner, reducing information redundancy, incorrect use, and other problems caused by non-standardization.
[0061] In one embodiment, if Figure 2 As shown, the site modification information management system includes:
[0062] The modification information storage and judgment module 21 is used to perform site modification information storage and judgment on the antibody site modification information in the resources extracted from the source resource library;
[0063] The site information normalization module 22 is connected to the modification information storage judgment module 21 and is used to normalize the site information of the antibody site modification information that meets the storage conditions;
[0064] The knowledge base updating module 23 is connected to the site information normalization module 22, and is used to determine whether the antibody site modification information after site information normalization exists in the knowledge base; if it is determined to exist in the knowledge base, it is determined whether to update the knowledge base based on the site modification information source score corresponding to the antibody site modification information; if it is determined not to exist in the knowledge base, the antibody site modification information after site information normalization is placed in the knowledge base.
[0065] In a specific embodiment, if Figure 4 As shown, the transformation information storage and judgment module 21 includes:
[0066] The therapeutic antibody type management module 211 is used to determine whether the therapeutic antibody type of the antibody site modification information in the resources extracted from the source resource library is the therapeutic antibody type specified by the knowledge base. If so, it meets the first collection condition; specifically, the antibody type of the site information source stored in the knowledge base is specified, such as monoclonal antibodies, bispecific antibodies, nano antibodies, etc. If the therapeutic antibody type of the antibody site modification information in the resources extracted from the source resource library is determined not to be of the specified type, its modification information will not be collected, such as Figure 5 shown.
[0067] The site modification factor management module 212 is connected to the therapeutic antibody type management module 211, and is used to determine whether the site modification factor of the antibody site modification information that meets the first collection condition is the site modification factor specified by the knowledge base. If so, it meets the second collection condition. Specifically, antibodies are artificially synthesized proteins. During production, storage, and in vivo use, they are easily affected by the physical and chemical aspects of the complex environment in vivo and in vitro, and undergo various forms of changes in physical and chemical properties, which in turn lead to increased immunogenicity, shortened half-life, and even failure. The modification of antibody sites can solve or reduce the impact of the above problems. Different site modifications will affect the performance of antibodies in different aspects (here referred to as factors), and different modifications have different focuses. By setting the modification factor type, classified management of a large number of site modification information can be achieved. The site modification factors of the site information collected by the knowledge base are specified, and the modification factors include improving solubility, reducing side effects, and improving antibody stability. When it is determined that the antibody site modification information involves other modification factors, this site modification information will not be collected, such as Figure 5 shown.
[0068] The site modification type management module 213 is connected to the site modification factor management module 212, and is used to determine whether the site modification type of the antibody site modification information that meets the second collection condition is the site modification type specified by the knowledge base, and if so, it meets the collection condition. Specifically, there are many ways to specify the site modification type of the site information stored in the knowledge base, such as amino acid mutation, site glycosylation modification, etc. The site modification type of the antibody site modification information that is determined not to be a specified modification type will not be included, such as Figure 5 shown.
[0069] In one embodiment, if Figure 4 As shown, the site information normalization module 22 includes:
[0070] The site coordinate management module 221 is used to use a preset numbering system to number the site coordinates of the sites of the antibody site modification information that meet the storage conditions; specifically, there are currently multiple numbering schemes to locate sites in antibodies, and the coordinates of the amino acids at the same site may be different under different numbering systems, which can easily lead to incorrect use of data. A unified numbering system such as Chothia is used in the entire knowledge base, and when collecting site modification information, its coordinates are converted or recalculated according to the specified numbering system.
[0071] The transformation site information scoring management module 222 is used to score the credibility of the antibody site transformation information based on the resources of the source of the antibody site transformation information to obtain the site transformation information source score of the corresponding antibody site transformation information; specifically, the antibody site transformation information comes from a variety of ways, such as obtaining through theoretical calculations using relevant software, obtaining through in vitro experiments of antibodies, etc. The credibility of the site information obtained by different means is different, and the significance for reference is also different. For example, the transformation information involved in the marketed antibodies may be more credible. There is no reliable site transformation information evaluation rule yet. We score it by the way the site transformation information is generated. The higher the score, the more reliable the site transformation information. For example, it can be stipulated that the scores of the site transformation information that lacks judgment information, is simply theoretically calculated, verified by in vitro wet experiments, verified by in vivo wet experiments, and has been marketed increase in sequence.
[0072] The antibody performance change management module 223 before and after the site modification is used to determine the antibody performance change before and after the site modification of the antibody site modification information; wherein, the antibody performance change before and after the site modification includes: no obvious change, better performance and worse performance. Specifically, not every site modification will have a positive effect on the antibody, and sometimes it will make the antibody performance worse. Even if the site modification information that has a negative impact on the antibody performance is still valuable, such as avoiding repeating the same mistakes. By dividing the changes into three situations of "no obvious change", "better performance" and "worse performance", most of the existing site modification information can be managed and convenient for subsequent use. In addition, when certain amino acids are present in specific positions, they will also affect the performance of the antibody, so "better performance" and "worse performance" will still be included in the knowledge base even if the antibody is not modified.
[0073] Through the above, a standardized management method for site modification information after the site modification information is collected and judged is realized, such as Figure 5 That is, for each site modification information in the resource, the relevant coordinates are converted and the relevant information is collected in a standardized manner according to the above-mentioned rules and methods such as "therapeutic antibody type management" and "site modification factor management", and the site modification information is numbered according to unified rules to provide standardized knowledge for the knowledge base and facilitate subsequent use.
[0074] In one embodiment, the knowledge base updating module 23 determines whether the site coordinate number of the antibody site modification information after site information normalization exists in the knowledge base; if it is determined to exist in the knowledge base, it determines whether to update the knowledge base based on the site modification information source score corresponding to the antibody site modification information; if it is determined not to exist in the knowledge base, the antibody site modification information after site information normalization is placed in the knowledge base, such as Figure 5 .
[0075] Among them, the method of determining whether to update the knowledge base based on the site modification information source score corresponding to the antibody site modification information includes:
[0076] Compare the site modification information source scores corresponding to the antibody site modification information with the site modification information source scores of the same antibody site modification information in the knowledge base; specifically, with the development of technology, the same site modification content will be verified in different ways and to different degrees at different time points. For the same site modification content, the corresponding score stored in the knowledge base is ScoreA, and the site information sorted this time is scored as ScoreB.
[0077] If the source score of the site modification information corresponding to the antibody site modification information is smaller than the source score of the antibody site modification information in the knowledge base, the knowledge base is not updated; specifically, if ScoreB < ScoreA, no update operation is performed on the knowledge base.
[0078] If the source score of the site modification information corresponding to the antibody site modification information is larger than the source score of the antibody site modification information in the knowledge base, the antibody site modification information in the knowledge base is updated; specifically, if ScoreB > ScoreA, the detailed site modification information at this site in the knowledge base is updated;
[0079] If the source score of the site modification information corresponding to the antibody site modification information is the same as the source score of the antibody site modification information in the knowledge base, it is selected whether to update the antibody site modification information in the knowledge base; specifically, if ScoreA = ScoreB, it is decided whether to update the knowledge base and make remarks after manual judgment.
[0080] The above is all the content of the method for constructing a site modification information knowledge base mainly based on therapeutic antibodies through the resource library management system and the site modification information management system, which solves the following technical problems:
[0081] 1. Solve the problem of difficult collection and update maintenance of various resources. The site modification information of therapeutic antibodies comes from various resources, such as published literature, public patents, antibody drug information disclosed by companies, etc. Most knowledge bases only utilize some types of resources when being constructed, such as only using literature resources, or only using the resources collected at that time. Therefore, various types of resources cannot be effectively utilized, and it is also very difficult to continuously collect and organize the resources. In addition, how to effectively manage the collected resources is also a problem.
[0082] In order to continuously collect and utilize various types of resources, the present invention collects and processes resources in an asynchronous form by constructing a resource pool, and maintains the status of each resource. Resources collected at different time points can be timely stored in the resource library, realizing the continuous collection of resources. In addition, by assigning a status (such as "unprocessed", "adopted", etc.) to each resource and maintaining the status, the chaos during resource processing can be reduced.
[0083] 2. Solve the problems of difficult structured management and information sorting of site modification information. There are various types of therapeutic antibodies, various types of site modifications, different reasons for site modifications, and very different effects after site modifications. How to organize and structure this complex information is a difficult problem. In addition, the credibility of each site modification information is different. If it is not treated differently, it is easy to cause information conflicts. However, there is currently no unified standard for how to effectively evaluate site modification information.
[0084] The present invention extracts and manages the site modification information in a standardized manner according to the therapeutic antibody type management module, the site modification factor management module, the site modification type management module, the antibody performance change management module before and after the site modification, etc., so that the extracted site information contains the specified entries and ensures that the values under each entry are derived from the same list. This structured processing of the site modification information scattered in different resources is conveniently stored in the knowledge base. At the same time, the present invention scores the reliability of each site modification information according to the "site modification information scoring management module", which not only solves the reliability assessment problem of the site modification information, but also can use this score to solve the conflict problem in the site modification information (the same site modification content selects the information with a high score).
[0085] In order to better describe the antibody evaluation and modification recommendation strategy based on the knowledge base, the following specific examples are now described.
[0086] The construction of the knowledge base can not only standardize the management of therapeutic antibody site modification information, but more importantly, use the knowledge base to evaluate and recommend antibody sequences to be modified. Most knowledge bases only have information query functions, and cannot effectively sort multiple antibody sequences to be modified, and it is difficult to provide modification suggestions for antibody sequences to be modified, which limits the scope of application of the knowledge base.
[0087] The constructed therapeutic antibody site modification information knowledge base is used to evaluate new antibody sequences and provide effective suggestions on how to modify them. Specifically, the antibody sequence evaluation system and the modification solution recommendation system are used to implement the antibody sequence evaluation method and the therapeutic antibody site modification solution recommendation method respectively.
[0088] The following describes the method of performing antibody sequence evaluation using the antibody sequence evaluation system in conjunction with specific embodiments.
[0089] When faced with problems such as antibody modification, it is sometimes necessary to evaluate and compare multiple antibody sequences to select a more suitable antibody sequence. However, there is currently a lack of unified standards for how to perform evaluation and comparison. In the constructed knowledge base, the present invention combines each "site modification factor" with the "change in antibody performance before and after site modification" to obtain a list of site information in the antibody sequence to be modified that has a positive or negative impact on performance.
[0090] In one embodiment, if Figure 6 As shown, the antibody sequence evaluation system 3 comprises:
[0091] A type identification module 31 is used to determine whether the therapeutic antibody type of each antibody sequence to be modified is the therapeutic antibody type specified in the knowledge base;
[0092] A site coordinate numbering module 32, connected to the type identification module 31, is used to use the preset numbering system adopted by the site coordinate management module 221 to number the site coordinates of each site of each antibody sequence to be modified that meets the type of therapeutic antibody for constructing the knowledge base;
[0093] The dominant site evaluation module 33 is connected to the site coordinate numbering module 32, and is used to check whether there is modified site information obtained in the knowledge base according to the change of better performance in each antibody sequence based on the site coordinate number of each antibody sequence; if it exists, the site modification factor corresponding to the site information is determined, and the site of the site information is used as the dominant site; specifically, in the knowledge base, the modified site information is obtained according to the change of better performance, or the site information that exists itself; check whether this sequence contains the above site information and classify it according to the site modification factor, and these site information are the "advantages" of this antibody. Antibodies with more "advantage" site information may have a better basis for further development.
[0094] The disadvantage site evaluation module 34 is connected to the site coordinate numbering module 32, and is used to check whether there is modified site information obtained in the knowledge base according to the change of performance deterioration in each antibody sequence based on the site coordinate number of each antibody sequence; if there is, the site modification factor corresponding to the site information is determined, and the site of the site information is used as a disadvantage site; specifically, in the knowledge base, the modified site information or the existing site information is obtained according to the change of performance deterioration; check whether this sequence contains the above site information and classify it according to the site modification factor, and these site information are the "disadvantages" of this antibody. Antibodies with more "disadvantage" site information may be more difficult to modify.
[0095] The evaluation result generating module 35 is connected to the advantageous site evaluation module and the disadvantageous site evaluation module, and is used to count the number of advantageous sites, the number of disadvantageous sites and the site modification factors corresponding to each site of each sequence based on the advantageous sites of each antibody sequence and the site modification factors corresponding to the advantageous sites and the disadvantageous sites and the site modification factors corresponding to the disadvantageous sites, so as to obtain the evaluation result of each antibody sequence, so as to rank the antibody sequences based on the number of disadvantageous sites of each antibody sequence. No disadvantageous sites need not be modified, and the fewer the disadvantageous sites, the higher the ranking.
[0096] Solve the problem of evaluating the developability potential of antibody sequences to be modified. Classify the site modification information in the knowledge base according to the changes in antibody performance before and after the site modification; then check how many advantageous sites and disadvantageous sites the modified antibody sequence has and classify and display the above sites according to the site modification factors; finally, sort multiple antibody sequences according to the number of "advantageous sites" and "disadvantageous sites", so as to provide decision-making references for users and decide which antibody sequences to prioritize for modification when resources are limited.
[0097] The following describes a method for recommending therapeutic antibody site modification schemes using a modification scheme recommendation system in conjunction with specific examples.
[0098] In one embodiment, if Figure 7 As shown, the transformation scheme recommendation system 4 includes:
[0099] A type identification module 41 is used to determine whether the therapeutic antibody type of the antibody sequence of the proposed modification solution is the therapeutic antibody type specified in the knowledge base;
[0100] A site coordinate numbering module 42, connected to the type identification module 41, is used to use the preset numbering system adopted by the site coordinate management module 221 to perform site coordinate numbering on each site of the antibody sequence of the recommended transformation scheme that meets the therapeutic antibody type for constructing the knowledge base;
[0101] The risk site assessment module 43 is connected to the site coordinate numbering module 42, and is used to check whether there is site information obtained in the knowledge base based on the site coordinate numbering of each antibody sequence after the transformation according to the change of performance deterioration; if there is, the site transformation factor of the corresponding site information is determined, and the site is used as a risk site; based on the site coordinate numbering of each antibody sequence, check whether there is site information before the transformation obtained in the knowledge base according to the change of better performance in each antibody sequence; if there is, the site transformation factor of the corresponding site information is determined, and the site is used as a risk site; specifically, in the knowledge base, the site information after the transformation is obtained according to the change of performance deterioration, or the site information that exists itself, to check whether the antibody sequence to be transformed contains these site information. If yes, mark it out, classify these site information according to the site transformation factor and give risk warning; obtain the site information before the transformation according to the change of better performance, and check whether the antibody sequence to be transformed contains these site information. If yes, mark it out, and classify these site information according to the site transformation factor and give risk warning.
[0102] The transformation scheme generation module 44 is connected to the risk site assessment module 43, and is used to use the site coordinate number of each risk site to check whether there is site information before the transformation obtained in the knowledge base according to the change of better performance; if there is, the corresponding site information before and after the transformation and the site transformation factors and site transformation information source scores corresponding to each site information are obtained to generate the corresponding transformation recommendation scheme. Specifically, in the knowledge base, the site information before and after the transformation is obtained according to the change of better performance, and whether this antibody sequence contains the site information before the transformation. If it does, the transformation opinions are classified according to the site transformation factors, and specific transformation suggestions (i.e., the corresponding site information after the transformation) are given.
[0103] Through the above method, the constructed knowledge base information is fully utilized, and the relevant risk sites for the modified antibody sequence are given (to determine the direction of subsequent modification), and even specific modification suggestions are given. Since each site modification information is scored and managed when the knowledge base is constructed, the specific modification suggestions given by the system will also give the credibility (score) of this modification suggestion, which is convenient for users to decide whether to adopt the modification suggestions recommended by the system.
[0104] In order to better illustrate the above therapeutic antibody site modification information management system, the present invention provides the following specific embodiments.
[0105] Example 1: A method for constructing and applying a knowledge base of therapeutic antibody site modification information.
[0106] The knowledge base construction and application method of the therapeutic antibody site modification information is implemented based on the therapeutic antibody site modification information management system;
[0107] The method comprises:
[0108] 1. System-related functional regulations:
[0109] Resource number management: A variety of numbering rules can be formulated. In this embodiment, the PubMed ID number is directly used to represent each resource.
[0110] Resource status management: There can be multiple statuses. In this embodiment, five statuses are specified, namely "unprocessed", "processing", "adopted", "not adopted" and "on hold".
[0111] Management of therapeutic antibody types: There can be a variety of antibody types, but in this example only monoclonal antibodies are used.
[0112] Management of site modification factors: There can be a variety of modification factors, but in this embodiment only two are included, namely, “reducing side effects” and “extending half-life”.
[0113] Site modification type management: There can be multiple modification types, which in this example only include amino acid mutations (or remain unchanged).
[0114] Site coordinate management: Any numbering system may be used, and in this embodiment, the EU numbering system is used.
[0115] Scoring management of modified site information: various scoring strategies can be formulated. In this embodiment, the score of modified site information lacking judgment information is 1, the score of modified information obtained by theoretical calculation alone is 2, the score of modified information verified by wet experiment is 3, and the score of modified information of marketed drugs is 4.
[0116] Management of antibody performance changes before and after site modification: A variety of changes can be specified, and two are specified in this embodiment, "better performance" and "worse performance".
[0117] 2. The knowledge base construction methods of antibody site modification information include:
[0118] Resource storage: In this embodiment, three documents are collected from the PubMed database, which are numbered 32404368, 31735912 and 30041038 according to the numbering rules. After querying, these three document resources are not in the current resource library, so all three documents are stored in the library and their status is set to "unprocessed".
[0119] Resource processing: According to the "unprocessed" status, the three resources 32404368, 31735912 and 30041038 are taken out from the resource library in turn. Each time one is taken out, its status is set to "processing". According to the site modification information acquisition and standardized arrangement method, the modification information in the three resources is processed, and the processing results are as follows:
[0120] Resource No. 32404368 contains a bispecific antibody. Since it does not meet the requirements in the first step, the status of this resource is reset to "Not Used" and the reason is noted;
[0121] The two resources numbered 31735912 and 30041038 contain therapeutic monoclonal antibodies. According to the provisions in the first step, the site modification information is extracted and saved in the knowledge base, and the status of these two resources is also set to "adopted". The site modification information obtained therefrom is as follows (in this embodiment, only a small part of the modification information is extracted from these two resources for describing the method of the present invention):
[0122] Table 1: Site modification information
[0123]
[0124] 3. Use the constructed knowledge base to evaluate the antibody sequences to be modified and recommend modification strategies:
[0125] In this example, two antibody sequences (antibody A and antibody B) are used to demonstrate how to use the constructed knowledge base. The amino acid conditions of the two sequences to be modified at some sites (the EU numbering system is used in this example, and this patent can support the use of any numbering system) are as follows:
[0126] Table 2: Amino acid status of the sequence at some sites
[0127] Location 234 235 252 254 256 428 310 Antibody A L L R Q V M S Antibody B L P Y T E F H
[0128] First, the knowledge base is used to evaluate the two sequences. The two L (leucine) at positions 234 and 235 in antibody A will cause side effects, and the M (methionine) at position 428 will shorten the half-life, both of which are disadvantageous sites; the Y (tyrosine), T (threonine) and E (glutamic acid) at positions 252, 254 and 256 of antibody B are conducive to extending the half-life, and the H (histidine) at position 310 is also conducive to extending the half-life. The evaluation statistics table is:
[0129] Table 3: Evaluation statistics of antibody sequences
[0130]
[0131] From the statistical table, we can see that there are more disadvantageous sites in antibody A, and antibody B itself contains more advantageous sites. Therefore, the basis for using antibody B for modification is better than that of antibody A.
[0132] Then the knowledge base is used to recommend a modification plan for the antibody sequence. Under the current knowledge base, antibody B has no disadvantageous sites, so there is no need to recommend a modification plan for it; the L234 / L235 site of antibody A can be mutated to A234 / A235, which will reduce the side effects of antibody A, and this modification plan has a score of 4, which is highly credible.
[0133] Example 2: A knowledge base construction and application method for site modification information of therapeutic monoclonal antibodies against tumors.
[0134] The research and development of antibody drugs generally includes target discovery, target selection, antigen preparation, antibody preparation technology selection and antibody function identification. Among them, the stability of antibodies is very important in the process of antibody preparation and antibody drug production, which is related to the binding stability and yield of antibody drugs.
[0135] In this example, we will further describe the present invention in conjunction with a therapeutic monoclonal antibody for tumors that we are currently developing. In the early stage of experiments, verifications, etc., we screened out an antibody with potential for treating tumors (the heavy chain part is QVQLQQSGAELVRPGTSVKVSCKASGNALTKHLIEWIKQRPGQGLEWIGV INPGSGGTNYNEKFKDKATLTADKSSSTAYMQLSSLTSDDSAVYFCARGSYDYDGFYYGL DYWGQGTSVTVSS, and the light chain part is DIQMTQSSSSFSVSLGERVTITCKASEDIYNRLAWYQQK PGNVPRLLISATTRLGTGVPSRFSGSGSGKDYSLSIASLQTEDVATYYCQQYRNTPYTFGGG TNLEIK). However, in the further development and production process, it was found that this antibody had problems such as poor stability and low yield, and it needed to be engineered. Using the therapeutic antibody site modification information management system provided in this embodiment, we first constructed a knowledge base of antibody site modification information; then used the constructed knowledge base to evaluate the sequence to be modified and obtain the corresponding modification scheme; finally, after experimental verification, it was found that the modification scheme provided by the present invention successfully achieved the expected goal. In this embodiment, the site modification information of therapeutic monoclonal antibodies from PubMed documents was collected (of course, the present invention can also be used for the collection and organization of site modification information of multiple therapeutic antibodies from more resources).
[0136] 1. System-related functional regulations:
[0137] Resource number management: A variety of numbering rules can be formulated. In this embodiment, PubMed's ID number is used to represent each resource.
[0138] Resource status management: There can be multiple statuses. In this embodiment, five statuses are specified, namely "unprocessed", "processing", "adopted", "not adopted" and "on hold".
[0139] Management of therapeutic antibody types: There can be a variety of antibody types, but in this example only monoclonal antibodies are used.
[0140] Site modification factor management: There can be a variety of modification factors. In this embodiment, factors such as "improving stability" and "improving binding strength" are used to illustrate.
[0141] Site modification type management: There can be multiple modification types, which in this example only include amino acid mutations (or remain unchanged).
[0142] Site coordinate management: Any numbering system can be used, and the Kabat numbering system is used in this embodiment.
[0143] Scoring management of modified site information: various scoring strategies can be formulated. In this embodiment, the score of modified site information lacking judgment information is 1, the score of modified information obtained by theoretical calculation alone is 2, the score of modified information verified by wet experiment is 3, and the score of modified information of marketed drugs is 4.
[0144] Management of changes in antibody performance before and after site modification: Various changes can be specified, such as "better performance after modification", "worse performance after modification", "better with this site", "bad with this site", etc.
[0145] 2. The knowledge base construction methods of antibody site modification information include:
[0146] Resource storage: In this embodiment, three documents are collected from the PubMed database (only these three documents are used as examples to demonstrate the present invention), and they are numbered 33543314, 27091886 and 8639672 according to the numbering rules. After querying, these three document resources are not in the current resource library, so all three documents are stored in the library and their status is set to "unprocessed".
[0147] Resource processing: Take out the above three resources from the resource library in turn according to the "unprocessed" status. Each time one is taken out, its status is set to "processing". According to the site modification information acquisition and standardized arrangement method, the modification information in the three resources is processed. These three resources all meet the requirements. According to the provisions in the first step, the site modification information is extracted and saved in the knowledge base, and the status of these resources is also set to "adopted". The site modification information obtained therefrom is as follows (in this embodiment, only a small part of the modification information is extracted from these three resources for describing the method of the present invention):
[0148] Table 4: Site modification information
[0149] Resource Number Site modification content Transformation Factors Performance changes Score 33543314 NG / NS / DG / DS sites in the CDR region Improved stability This location is not good 3 27091886 DG / DS / DT / DD sites in CDR regions Improved stability This location is not good 3 8639672 DG sites in CDR regions Improve bonding strength This location is not good 3
[0150] 3. Use the constructed knowledge base to evaluate the antibody sequences to be modified and recommend modification strategies:
[0151] In this embodiment, we used the antibody sequence under development (the amino acid sequence of the heavy chain is QVQLQQSGAELVRPGTSVKVSCKASGNALTKHLIEWIKQRPGQGLEWIGVINPGSGGTNYNEKFKD KATLTADKSSSTAYMQLSSLTSDDSAVYFCARGSYDYDGFYYGLDYWGQGTSVTVSS, and the amino acid sequence of the light chain is DIQMTQSSSSFSVSLGERVTITCKASEDIYNRLAWYQQKP GNVPRLLISATTRLGTGVPSRFSGSGSGKDYSLSIASLQTEDVATYYCQQYRNTPYTFGGGT NLEIK). Using the constructed knowledge base, we found that the antibody sequence (heavy chain) CDR region contains the "DG" amino acid sequence, and this site will have side effects on the antibody, which provides a direction for our subsequent antibody modification.
[0152] Then we performed amino acid mutation on this antibody sequence and generated 3 mutant sequences, namely Mut1 (DG mutated to EG), Mut2 (DG mutated to DA), and Mut3 (DG mutated to DS). Experimental determination showed that by mutating the DG site, the stability problem caused by isomerization of the DG site can be effectively alleviated, and the yield can be improved. The specific results are shown in the table below:
[0153] Table 5: Experimental results
[0154] Antibody Amino acid sequence of mutation region Expression level (mg / L) Antibody concentration (mg / ml) WT DG 33.9 0.88 Mut1 EG 32.4↓ 0.84↓ Mut2 DA 36.4↑ 0.99↑ Mut3 DS 34.0↑ 1.02↑
[0155] Antibody concentration was determined using the Thermo Scientific NanoDrop instrument and its accompanying software; expression levels were obtained by dividing the total amount of antibody produced by the cell expression volume.
[0156] Similar to the principle of the above embodiment, the present invention provides a method for managing therapeutic antibody site modification information.
[0157] The following provides specific embodiments in conjunction with the accompanying drawings:
[0158] like Figure 8 A schematic diagram showing a flow chart of a method for managing therapeutic antibody site modification information in an embodiment of the present invention.
[0159] The method comprises:
[0160] Step S1: constructing a knowledge base of therapeutic antibody site modification information;
[0161] In detail, Fig. 9 As shown, step S1 includes:
[0162] Step S11: performing resource library management on each resource corresponding to the antibody site modification information source collected to construct a source resource library containing multiple resources; wherein each resource in the source resource library corresponds to a resource number and a resource status;
[0163] Step S12: performing site modification information storage judgment on the antibody site modification information in the resources extracted from the source resource library, and normalizing the site modification information of the antibody site modification information that meets the storage conditions, so as to construct a knowledge base containing a plurality of antibody site modification information after site modification information normalization; wherein each antibody site modification information in the knowledge base respectively corresponds to a site coordinate number, a site modification factor, a change in antibody performance before and after the site modification, and a site modification information source score;
[0164] In one embodiment, step S11 includes:
[0165] The newly collected resources corresponding to the antibody site modification information sources are numbered according to the numbering rules;
[0166] Based on the ID of each resource, query whether there is a corresponding resource in the current source resource library, and incorporate the resources that do not exist in the source resource library into the source resource library;
[0167] Assign a resource status of unprocessed state to the resource newly included in the source resource library;
[0168] Extracting resources to be processed from the source resource library and returning the corresponding resources to the source resource library after processing is completed, and sending the processing status of the resources in real time to update the resource status of the corresponding resources in real time;
[0169] Use resource ID and / or resource status to query and perform statistical analysis on resources in the source resource library.
[0170] In one embodiment, the step S12 includes:
[0171] Performing site modification information storage and judgment on the antibody site modification information in the resources extracted from the source resource library;
[0172] Normalize the site information of antibody site modification that meets the collection conditions;
[0173] Determine whether the antibody site modification information after site information normalization exists in the knowledge base; if it is determined to exist in the knowledge base, determine whether to update the knowledge base based on the site modification information source score corresponding to the antibody site modification information; if it is determined not to exist in the knowledge base, put the antibody site modification information after site information normalization into the knowledge base.
[0174] In one embodiment, performing site modification information storage determination on antibody site modification information in resources extracted from a source resource library includes:
[0175] Determine whether the therapeutic antibody type of the antibody site modification information in the resource extracted from the source resource library is the therapeutic antibody type specified by the knowledge base, and if so, it meets the first collection condition;
[0176] Determine whether the site modification factor of the antibody site modification information that meets the first storage condition is a site modification factor specified in the knowledge base, and if so, it meets the second storage condition;
[0177] It is determined whether the site modification type of the antibody site modification information that meets the second storage condition is the site modification type specified in the knowledge base, and if so, it meets the storage condition.
[0178] In one embodiment, normalizing the site information of the antibody site modification information that meets the storage conditions includes:
[0179] The site coordinates of the sites of antibody site modification information that meet the collection conditions are numbered using a preset numbering system;
[0180] Scoring the credibility of the antibody site modification information based on the resources of the source of the antibody site modification information to obtain a site modification information source score corresponding to the antibody site modification information;
[0181] Determine the change in antibody performance before and after the site modification of the antibody site modification information; wherein the change in antibody performance before and after the site modification includes: a change in which there is no obvious change, a change in which the performance is better, and a change in which the performance is worse.
[0182] In one embodiment, the method for determining whether to update the knowledge base based on the site modification information source score corresponding to the antibody site modification information includes: comparing the site modification information source score corresponding to the antibody site modification information with the site modification information source score of the same antibody site modification information existing in the knowledge base; if the site modification information source score corresponding to the antibody site modification information is smaller than the site modification information source score of the antibody site modification information in the knowledge base, the knowledge base is not updated; if the site modification information source score corresponding to the antibody site modification information is larger than the site modification information source score of the antibody site modification information in the knowledge base, the antibody site modification information in the knowledge base is updated; if the site modification information source score corresponding to the antibody site modification information is the same as the site modification information source score of the antibody site modification information in the knowledge base, manually selecting whether to update the antibody site modification information in the knowledge base.
[0183] Step S2: Based on the constructed knowledge base, antibody evaluation is performed on one or more antibody sequences to be modified and / or modification recommendations are made on antibody sequences for which modification schemes are to be recommended.
[0184] Specifically, the method of performing antibody evaluation on one or more antibody sequences to be modified includes: numbering the site coordinates of each site of one or more antibody sequences to be modified that meet the therapeutic antibody type specified in the knowledge base, and evaluating the dominant sites and the inferior sites of each antibody sequence based on the knowledge base to obtain the evaluation results of each antibody sequence, so as to perform modification sorting on each antibody sequence based on the evaluation results of each antibody sequence; wherein the evaluation results of each antibody sequence include: the number of dominant sites, the number of inferior sites, and the site modification factors corresponding to the dominant sites and the inferior sites, respectively;
[0185] The method of recommending the modification of an antibody sequence for which a modification scheme is to be recommended includes: numbering the site coordinates of each site of the antibody sequence for which a modification scheme is to be recommended that meets the therapeutic antibody type specified in a knowledge base, and performing a risk site assessment on the antibody sequence based on the knowledge base, and obtaining a modification recommendation scheme for the antibody sequence for recommendation; wherein the modification recommendation scheme includes: site information before and after modification, and site modification factors corresponding to each site information and a site modification information source score.
[0186] In one embodiment, if Fig.10 As shown, the method of performing antibody evaluation on one or more antibody sequences to be modified includes:
[0187] Step S211: determining whether the therapeutic antibody type of each antibody sequence to be modified is the therapeutic antibody type specified in the knowledge base;
[0188] Step S212: using the same preset numbering system as that used to construct the knowledge base, numbering the site coordinates of each site of each antibody sequence to be modified that meets the therapeutic antibody type for constructing the knowledge base;
[0189] Step S213: Checking whether there is modified site information obtained from the knowledge base according to the change of better performance in each antibody sequence based on the site coordinate number of each antibody sequence; if there is, determining the site modification factor corresponding to the site information, and taking the site of the site information as the dominant site;
[0190] Step S214: Checking whether there is modified site information obtained from the knowledge base according to the change in performance degradation in each antibody sequence based on the site coordinate number of each antibody sequence; if there is, determining the site modification factor corresponding to the site information, and treating the site of the site information as a disadvantageous site;
[0191] Step S215: Based on the dominant sites and the site modification factors corresponding to the dominant sites and the inferior sites and the site modification factors corresponding to the inferior sites of each antibody sequence, the number of dominant sites, the number of inferior sites and the site modification factors corresponding to each site of each sequence are counted to obtain the evaluation result of each antibody sequence, so as to rank the antibody sequences based on the number of inferior sites of each antibody sequence.
[0192] In one embodiment, if Fig.11 As shown, the recommended methods for modifying the antibody sequence of the recommended modification scheme include:
[0193] Step S221: determining whether the therapeutic antibody type of the antibody sequence of the proposed modification solution is the therapeutic antibody type specified in the knowledge base;
[0194] Step S222: using the same preset numbering system as that used to construct the knowledge base, numbering the site coordinates of each site of the antibody sequence of the therapeutic antibody type to be recommended for transformation that meets the requirements of the knowledge base;
[0195] Step S223: Checking whether there is site information after transformation obtained in the knowledge base according to the change of performance deterioration in each antibody sequence based on the site coordinate number of each antibody sequence; if there is, determining the site transformation factor corresponding to the site information, and taking the site as a risk site; checking whether there is site information before transformation obtained in the knowledge base according to the change of better performance in each antibody sequence based on the site coordinate number of each antibody sequence; if there is, determining the site transformation factor corresponding to the site information, and taking the site as a risk site;
[0196] Step S224: Use the site coordinate number of each risk site to check whether there is site information before transformation obtained in the knowledge base based on the change with better performance; if so, obtain the corresponding site information before and after transformation, as well as the site transformation factors and site transformation information source scores corresponding to each site information, to generate a corresponding transformation recommendation plan.
[0197] Since the implementation principle of the therapeutic antibody site modification information management method has been described in the above embodiments, it will not be repeated here.
[0198] like Fig.12 A schematic diagram showing the structure of a therapeutic antibody site modification information management terminal in an embodiment of the present invention.
[0199] The therapeutic antibody site modification information management terminal 100 includes: a memory 101 and a processor 102. The memory 101 is used to store computer programs; the processor 102 runs the computer programs to achieve the following Figure 8 The therapeutic antibody site modification information management method.
[0200] Optionally, the number of the memory 101 can be one or more, the number of the processor 102 can be one or more, and Figure 8 Take one as an example.
[0201] Optionally, the processor 102 in the therapeutic antibody site modification information management terminal 100 will perform the following steps: Figure 1 In the above steps, one or more instructions corresponding to the process of the application are loaded into the memory 101, and the processor 102 runs the application stored in the first memory 101, thereby achieving the following Figure 7 Various functions in the therapeutic antibody site engineering information management method.
[0202] Optionally, the memory 101 may include but is not limited to high-speed random access memory and non-volatile memory. For example, one or more disk storage devices, flash memory devices or other non-volatile solid-state storage devices; the processor 102 may include but is not limited to a central processing unit (CPU), a network processor (NP), etc.; it may also be a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic devices, discrete gates or transistor logic devices, discrete hardware components.
[0203] Optionally, the processor 102 can be a general-purpose processor, including a central processing unit (CPU), a network processor (NP), etc.; it can also be a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic devices, discrete gate or transistor logic devices, discrete hardware components.
[0204] The present invention also provides a computer-readable storage medium storing a computer program, wherein the computer program is executed as follows: Figure 8 Therapeutic antibody site modification information management method shown. The computer-readable storage medium may include, but is not limited to, a floppy disk, an optical disk, a CD-ROM (read-only optical disk memory), a magneto-optical disk, a ROM (read-only memory), a RAM (random access memory), an EPROM (erasable programmable read-only memory), an EEPROM (electrically erasable programmable read-only memory), a magnetic card or an optical card, a flash memory, or other types of media / machine-readable media suitable for storing machine-executable instructions. The computer-readable storage medium may be a product that is not connected to a computer device, or it may be a component that has been connected to a computer device for use.
[0205] In summary, the therapeutic antibody site modification information management system, method, terminal and medium of the present invention, by managing the resource library of each resource corresponding to the source of the collected antibody site modification information, constructing the source resource library, performing site modification information storage and judgment on the antibody site modification information in the resources extracted from the source resource library, and normalizing the site information of the antibody site modification information that meets the storage conditions to construct a knowledge base; based on the knowledge base, the antibody sequence to be modified is evaluated for the advantage and disadvantage sites to obtain the evaluation results, and the antibody sequence to be recommended for the modification scheme is evaluated for the risk site to obtain the modification recommendation scheme of the antibody sequence. The present invention realizes the systematic collection and update of the antibody site modification information, standardized arrangement, storage, and formation of the knowledge base, and can use this knowledge base to realize the development potential evaluation, sorting and modification opinion recommendation of the antibody sequence to be modified. This will facilitate antibody developers and other personnel to use a large amount of existing knowledge to quickly and economically develop and modify antibody sequences, and accelerate the research and development, production and other processes of antibody drugs. Therefore, the present invention effectively overcomes the various shortcomings in the prior art and has a high industrial utilization value.
[0206] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the technology may modify or change the above embodiments without violating the spirit and scope of the present invention. Therefore, all equivalent modifications or changes made by a person of ordinary skill in the art without departing from the spirit and technical ideas disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. A therapeutic antibody site modification information management system, characterized in that: The system comprises: A resource library management system is used to manage the collected resources corresponding to the antibody site modification information source to build a source resource library containing multiple resources; wherein each resource in the source resource library corresponds to a resource number and a resource status; A site modification information management system, connected to the resource library management system, is used to perform site modification information storage and judgment on the antibody site modification information in the resources extracted from the source resource library, and to perform site modification information normalization on the antibody site modification information that meets the storage conditions, so as to construct a knowledge base containing a plurality of antibody site modification information after site modification information normalization; wherein each antibody site modification information in the knowledge base corresponds to a site coordinate number, a site modification factor, a change in antibody performance before and after site modification, and a site modification information source score; An antibody sequence evaluation system, connected to the site modification information management system, is used to number the site coordinates of each site of one or more antibody sequences to be modified that meet the therapeutic antibody type specified in the knowledge base, and evaluate the dominant sites and the inferior sites of each antibody sequence based on the knowledge base to obtain the evaluation results of each antibody sequence, so as to perform modification sorting on each antibody sequence based on the evaluation results of each antibody sequence; wherein the evaluation results of each antibody sequence include: the number of dominant sites, the number of inferior sites, and the site modification factors corresponding to the dominant sites and the inferior sites, respectively; A modification scheme recommendation system is connected to the site modification information management system, and is used to number the site coordinates of each site of the antibody sequence of the therapeutic antibody type to be recommended for the modification scheme that meets the requirements of the knowledge base, and to evaluate the risk sites of the antibody sequence based on the knowledge base, and obtain a modification recommendation scheme for the antibody sequence; wherein the modification recommendation scheme includes: site information before and after modification, and site modification factors corresponding to each site information and a site modification information source score.
2. The therapeutic antibody site modification information management system according to claim 1, characterized in that: The resource library management system includes: A resource numbering management module is used to number each newly collected resource corresponding to the antibody site modification information source according to the numbering rules; A resource entry management module, connected to the resource number management module, is used to query whether there is a corresponding resource in the current source resource library based on the number of each resource, and to include resources that do not exist in the source resource library into the source resource library; A resource status management module, connected to the resource storage management module, is used to assign a resource status of an unprocessed state to a resource newly added to the source resource library; A resource processing management module, connected to the resource status management module, is used to extract the resources required by the site modification information management system from the source resource library and send them to the site modification information management system for processing, and return the corresponding resources to the source resource library after processing, and send the processing status of the resources to the resource status management module in real time to update the resource status of the corresponding resources in real time; wherein the types of resource status include: resource unprocessed status, resource processing status, resource adopted status, resource not adopted status and resource shelved status; The resource query management module is used to query and perform statistical analysis on resources in the source resource library using resource numbers and / or resource status.
3. The therapeutic antibody site modification information management system according to claim 2, characterized in that: The site modification information management system comprises: A modification information collection and judgment module is used to perform site modification information collection and judgment on the antibody site modification information in the resources extracted from the source resource library; A site information normalization module, connected to the modification information storage judgment module, is used to normalize the site information of the antibody site modification information that meets the storage conditions; A knowledge base update module is connected to the site information normalization module, and is used to determine whether the antibody site modification information after site information normalization exists in the knowledge base; if it is determined to exist in the knowledge base, it is determined whether to update the knowledge base based on the site modification information source score corresponding to the antibody site modification information; if it is determined not to exist in the knowledge base, the antibody site modification information after site information normalization is placed in the knowledge base.
4. The therapeutic antibody site modification information management system according to claim 3, characterized in that: The transformation information storage and judgment module includes: The therapeutic antibody type management module is used to determine whether the therapeutic antibody type of the antibody site modification information in the resource extracted from the source resource library is the therapeutic antibody type specified by the knowledge base, and if so, it meets the first storage condition; A site modification factor management module, connected to the therapeutic antibody type management module, is used to determine whether the site modification factor of the antibody site modification information that meets the first storage condition is a site modification factor specified in the knowledge base, and if so, it meets the second storage condition; The site modification type management module is connected to the site modification factor management module and is used to determine whether the site modification type of the antibody site modification information that meets the second storage condition is the site modification type specified by the knowledge base, and if so, it meets the storage condition.
5. The therapeutic antibody site modification information management system according to claim 4, characterized in that: The site information normalization module includes: A site coordinate management module is used to use a preset numbering system to number the site coordinates of the sites of antibody site modification information that meet the storage conditions; A modification site information scoring management module, used to score the credibility of the antibody site modification information based on the resources of the source of the antibody site modification information, so as to obtain a site modification information source score corresponding to the antibody site modification information; The antibody performance change management module before and after site modification is used to determine the antibody performance change before and after site modification of the antibody site modification information; wherein the antibody performance change before and after site modification includes: changes without obvious changes, changes with better performance, and changes with worse performance.
6. The therapeutic antibody site modification information management system according to claim 5, characterized in that: The method of determining whether to update the knowledge base based on the site modification information source score corresponding to the antibody site modification information includes: Comparing the site modification information source score corresponding to the antibody site modification information with the site modification information source score of the same antibody site modification information existing in the knowledge base; If the site modification information source score corresponding to the antibody site modification information is smaller than the site modification information source score of the antibody site modification information in the knowledge base, the knowledge base is not updated; If the site modification information source score corresponding to the antibody site modification information is greater than the site modification information source score of the antibody site modification information in the knowledge base, updating the antibody site modification information in the knowledge base; If the site modification information source score corresponding to the antibody site modification information is the same as the site modification information source score of the antibody site modification information in the knowledge base, it is manually selected whether to update the antibody site modification information in the knowledge base.
7. The therapeutic antibody site modification information management system according to claim 5, characterized in that: The antibody sequence evaluation system comprises: A type identification module is used to determine whether the therapeutic antibody type of each antibody sequence to be modified is the therapeutic antibody type specified in the knowledge base; A site coordinate numbering module, connected to the type identification module, for performing site coordinate numbering on each site of each antibody sequence to be modified that meets the type of therapeutic antibody for constructing the knowledge base using a preset numbering system adopted by the site coordinate management module; A dominant site evaluation module, connected to the site coordinate numbering module, is used to check whether there is modified site information obtained in the knowledge base according to the change of better performance in each antibody sequence based on the site coordinate number of each antibody sequence; if so, determine the site modification factor corresponding to the site information, and use the site of the site information as the dominant site; A disadvantage site evaluation module, connected to the site coordinate numbering module, is used to check whether there is modified site information obtained in the knowledge base according to the change of performance degradation in each antibody sequence based on the site coordinate number of each antibody sequence; if so, determine the site modification factor corresponding to the site information, and use the site of the site information as a disadvantage site; The evaluation result generation module is connected to the dominant site evaluation module and the inferior site evaluation module, and is used to count the number of dominant sites, the number of inferior sites and the site modification factors corresponding to each site of each sequence based on the dominant sites of each antibody sequence and the site modification factors corresponding to the dominant sites and the inferior sites and the site modification factors corresponding to the inferior sites, so as to obtain the evaluation result of each antibody sequence, so as to rank the modification of each antibody sequence based on the number of inferior sites of each antibody sequence.
8. The therapeutic antibody site modification information management system according to claim 5, characterized in that: The transformation scheme recommendation system includes: A type identification module is used to determine whether the therapeutic antibody type of the antibody sequence of the recommended transformation solution is the therapeutic antibody type specified in the knowledge base; A site coordinate numbering module, connected to the type identification module, is used to use the preset numbering system adopted by the site coordinate management module to perform site coordinate numbering on each site of the antibody sequence of the recommended transformation scheme that meets the therapeutic antibody type for constructing the knowledge base; A risk site assessment module, connected to the site coordinate numbering module, is used to check whether there is site information after transformation obtained in the knowledge base according to the change of performance deterioration in each antibody sequence based on the site coordinate number of each antibody sequence; if so, determine the site transformation factor corresponding to the site information, and use the site as a risk site; check whether there is site information before transformation obtained in the knowledge base according to the change of better performance in each antibody sequence based on the site coordinate number of each antibody sequence; if so, determine the site transformation factor corresponding to the site information, and use the site as a risk site; The transformation plan generation module is connected to the risk site assessment module, and is used to use the site coordinate number of each risk site to check whether there is site information before transformation obtained in the knowledge base according to the change with better performance; if so, the corresponding site information before and after transformation and the site transformation factors and site transformation information source scores corresponding to each site information are obtained to generate a corresponding transformation recommendation plan.
9. A method for managing therapeutic antibody site modification information, characterized in that: The method comprises: Construct a knowledge base of therapeutic antibody site modification information; Based on the constructed knowledge base, antibody evaluation is performed on one or more antibody sequences to be modified and / or modification recommendations are made for antibody sequences for which modification schemes are to be recommended; Wherein, the method of constructing a knowledge base of therapeutic antibody site modification information includes: Performing resource library management on each resource corresponding to the antibody site modification information source collected to construct a source resource library containing multiple resources; wherein each resource in the source resource library corresponds to a resource number and a resource status; Performing site modification information storage and judgment on the antibody site modification information in the resources extracted from the source resource library, and normalizing the site modification information of the antibody site modification information that meets the storage conditions, so as to construct a knowledge base containing a plurality of antibody site modification information after normalization of the site modification information; wherein each antibody site modification information in the knowledge base respectively corresponds to a site coordinate number, a site modification factor, a change in antibody performance before and after the site modification, and a site modification information source score; Methods for antibody evaluation of one or more antibody sequences to be modified include: Numbering the site coordinates of each site of one or more antibody sequences to be modified that meet the therapeutic antibody type specified in the knowledge base, and evaluating the dominant sites and the inferior sites of each antibody sequence based on the knowledge base to obtain the evaluation results of each antibody sequence, so as to perform modification sorting on each antibody sequence based on the evaluation results of each antibody sequence; wherein the evaluation results of each antibody sequence include: the number of dominant sites, the number of inferior sites, and the site modification factors corresponding to the dominant sites and the inferior sites, respectively; The recommended methods for modifying the antibody sequences for which modification is recommended include: The site coordinates of each site of the antibody sequence of the therapeutic antibody type to be recommended for modification that meets the requirements of the knowledge base are numbered, and the risk site of the antibody sequence is evaluated based on the knowledge base, and a modification recommendation for the antibody sequence is obtained for recommendation; wherein the modification recommendation includes: site information before and after modification, and site modification factors corresponding to each site information and a site modification information source score.
10. A therapeutic antibody site modification information management terminal, characterized in that: include: one or more memories and one or more processors; The one or more memories are used to store computer programs; The one or more processors, connected to the memory, are configured to run the computer program to perform the method according to claim 9.
11. A computer-readable storage medium, characterized in that: A computer program is stored, which, when executed by one or more processors, performs the method as claimed in claim 9.
